4. Given the limitations of the study and the specific findings with regard to eGFR changes in those with baseline eGFR>60, use of the term 'CKD progression' would be better avoided and may represent something of an overstatement of the findings. The baseline CKD status was taken from only one eGFR, which is a limitation that is acknowledged, but it means that some patients may not have had CKD to begin with , so 'CKD progression' would not be accurate -'eGFR decline' might be a better term.
5. It is interesting that hypertension is included with other cardiovascular disease. Given the high prevalence of hypertension in people with CKD, it results in a very high apparent prevalence of CVD in this study. In addition, hypertension is both a preciptating factor and a result of renal disease and I would recommend treating it separately in the descriptions and analyses (or at least sensitivity analysis with hypertension treated separately).
6. While the definition of normal and high dose is well described and justified, these definitions do not mean much to the average prescriber. For example -is 'high dose' aspirin equivalent to about 300mg per day and 'normal' equivalent to 75mg, or is that not the case. Some examples like this to put the meaning of DDD in context would be very helpful (particularly is these findings are going to influence practice in any way).
7. It is not clear from the descriptive tables how many people had baseline eGFR in each CKD stage. This might be more useful than the current table 2 which just gives information on median eGFR [IQR] 8. Line 10 page 14 represents a finding that should perhaps be the key finding of the paper -that there was no association between normal or high dose aspirin use and CKD progression in people with CKD 3 -5. Consider refocusing the paper with this being more prominent. For clinicians dealing with CKD in general practice, the implication that we should be considering aspirin treatment in people without current CKD (or very mild impairment of renal function) is perhaps not so relevant. This is treated fairly well in the first paragraph of the discussion, but the overall conclusion and the abstract conclusion then claim that high dose aspirin decreases the risk of CKD progression which is an overstatement given the findings.
9. There is an implication of causality in some of the statements used that is probably inappropriate given the study design. For example -in the first paragraph of the discussion 'high dose aspirin prescribing significantly decreased the risk of CKD progression' might be better worded ' high dose aspirin prescribing was associated with lower risk of eGFR decline' Other minor points:
1. Some aspects of the wording could be imporved. The first sentence of the background is poorly worded for example.
2. The sentence about the use of low dose aspirin and NSAIDS in line 37 page 5 (background) makes a statement that cannot be justified from the BNF reference used -is there study evidence that this is true? 3. Was there no ACR data avaliable? Or was it just that there was a lot of missing data? It might be useful to describe the degree of missing ACR data.
4. Consider a sensitivity analysis using the CKDEPI equation to define eGFR given its better risk profile in CKD.
5. The description of Index of Multiple Deprivation would benefit from syaing that it was national IMD if this was the case.
6. Page 13 line 12 'the eGFR decline rate profile'. What does this statement mean? Does it refer to table 4? Can the statement be justified? 7. Table 3 -age groups would be more helpful than mean (SD). Reword 'CKD progression' 8. Figure - the flow diagram is helpful, but might benefit from inclusion of the 9 practices with population about 40000 mentioned in the methods. Why were all 9 practices not used -what was the reason for their exclusion? This is not clear in the paper
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GENERAL COMMENTS
This paper evaluates the effect of NSAIDs, aspirin and paracetamol analgesia dose prescribing on chronic kidney disease (CKD) progression. In general is a well-written and interesting paper. However there are many questions that need to be addressed.
Mayor comments:
Methods:
1. The design used in this analysis is not clearly stated. It seems a case control analysis given that logistic regression and OR are calculated. 2. Cohort definition: study period is not clearly defined. i.e were patients 40 years and over at January 1 st ? or could patients be 40 years and over after this date? 3. Are patients newly diagnosed CKD patients? 4. Cumulative exposure definition: a. With respect to cumulative exposure definition. It is described that "All prescriptions from January 1 st up to the last eGFR" were included in the cumulative exposure (page 8 line 25). However it is also stated that prescription given before the study "start date" and the date of the fist eGFR were included (page 9, line 18). Please define "start date", and "last eGRF" (does it mean second, third??) and clarify this point. This is really important to set the aim of this research in whether analgesia use is associated with CKD progression or whether analgesia use increases the risk of developing CKD. b. As far as I understood, cumulative duration (and dose) of analgesia, as it was measured in this study, means to consider all prescription regardless of whether or not they were consecutively prescribed. However this is not exactly similar to continuous duration in which a number of days (gap) between the end of a prescription and the start of the consecutive one has to be permitted to define "continuous" use. Aspirin prescriptions are probably used for prophylaxis so we can assume "continuous", however NSAIDs can be discontinuous. Moreover, this is important as the term "short-term" is used in the title and this usually refers to "continuous duration". The term "long-term users" in also used in the discussion section referring to other studies". Please define these terms (short/long term) in the methods section or use other names according to those defined in methods. 5. Regarding to covariates, a. Description of codes used for potential confounders are welcome. This helps to reproduce variables in similar studies (supplementary table online??). b. On page 10, line 17, it is described that co-morbidity will be defined as the presence of those diseases "at any point throughout the study period", similarly to co-drugs ("during the study period", line 38 of the same page). Will patient"s follow-up be censored at the last eGFR measure? Or, I assume they will be measured before the last eGRF. Could you please clarify this point?. In addition, co-morbidities are chronic, however co-medication could be measured far from the endpoint. Could you please clarify this point as well? 6. Define in methods which is the "baseline CKD stage" (page 11, line23) Discussion 7. High dose NSAIDs has been related to CKD progression however this was not observed in this analysis, could it be due to different cut-off point for dose used in previous studies? 8. A more detailed description on possible differences in methods applied in previous studies, which could explain different results, is desirable (i.e different definition for cumulative/continuous duration, cut-off points and different designs).
Minor comments
Methods 1. A more detailed explanation on total patients included in the database as well as number of GPs, etc will be welcome.
Results:
1. Total numbers (counts) should be added to tables in addition to OR. Table 5 needs numbers for CKD progression and CKD non-progression. 2. "reserve" has to be changed by "preserve" (page 15, line 27) 3. Another limitation (although it is probably a minor limitation) is analgesia prescribed in hospital, what is probably missing in a primary care based database.
Discussion:
1. Once patients are diagnosed with chronic renal insufficiency, they are probably advised to discontinue (or not to use) NSAIDs as these drugs interfere with potassium excretion and may further compromise glomerular filtration rate. In guidelines but also in patients information leaflet for NSAIDs it is recommended to use these drugs with caution if CKD exists. Might this situation have an impact on results? 2. With respect to the significant lack of progression using higher dose of aspirin in normal or mildly impaired eGFR in contrast with the non-significant effect in stage 3-5 CKD, as the authors stated, "it is unclear as to whether aspirin is renoprotective independent of its cardioprotective effect". Thus potential differences between patients with/without CVD could be explored, which provides different information than just simple inclusion of those variables in the models. 3. As the authors stated, non significant effect of high dose use of aspirin in patients at stage 3-5 CDK could be indeed due to few numbers; however, might this group be less prone to be influence by the cardioprotective effect of aspirin as they have CKD already established? IV. The inclusion of a wide range of CKD patients from a general practice setting V. Adjustment for relevant co-morbidity and co-drug therapy in CKD patients.
VERSION 1 -AUTHOR RESPONSE
Most of these points are included in the strengths and limitations bullet points (p4).
We have made changes to the introduction including adding "Few studies have used standardised drug doses to quantify the unsafe levels of use with invalid or arbitrary definitions of maintenance or high levels of analgesic use" and "Few studies have examined the effect of NSAIDs, aspirin and paracetamol prescribing on eGFR decline amongst the CKD population" to try and highlight these points more clearly (p7).
2. The paper (including abstract) would benefit from greater clarity about the study design. Specifically, the variation in follow up time is not clear -were some people followed up after the full 2 years while some only 'joined' the study towards the end of 2010 and only had 90 days of time in which to 'progress'? For some patients there must have been eGFR values between the first and last and the pattern of change in these is unlikely to have been linear decline (or completely stable). Better description of this pattern would be helpful -perhaps by an additional figure? Also, the authors could acknowledge more clearly the limitations of using only last and first eGFR in the measure of eGFR decline (if this is how it was done)
Authors" response: We apologise for the confusion, the reviewer makes a good point about variation to follow-up. It is correct that some patients would not have as long a follow-up as their eGFR measurements may have occurred after the 1st Jan 2009 or before the 31st of Dec 2010, however, the mean follow-up time (interval between the first and last eGFR) was 270 days (stated in the results).
To better clarify the design, the abstract now says "the outcome measure was defined as a >5ml/min/1.73m2/year eGFR decline between the first and last eGFR" (p3).
We have re-written the methods -study cohorts section which now reads (p7): "Patients aged 40 years and over with at least one eGFR measurement from the January 1st 2009 up to December 31st 2010 were identified (2-year study period). Of these, patients with two or more eGFR measurements during the 2-year study period were eligible for inclusion and formed the study cohort ( Figure 1 ). Patients aged under 40 years old on January 1st 2009 were excluded because stage 3-5 CKD prevalence is low in this age group."
We have also expanded on the issue of follow-up time in the methods (p9), it now reads: "Therefore, patients had a maximum follow-up interval of up to 2 years between the first and last eGFR and a minimal interval of 90 days. Only the first and last eGFR measurements during the study period were used to calculate the eGFR decline rate."
Secondly, the reviewer correctly identifies that the pattern of eGFR measurements for some patients may not have been linear between the first and last eGFR, there wasn"t a particular pattern of note. Because patients with short intervals between eGFR measurements (<90 days) were excluded, it was likely that patients with CKD remained who tended to have measurements 6 months to years for routine monitoring and these patients trended to have more linear decline. The median number of eGFR measurements which was 3 (IQR 2-4) over 2 years also fits with a monitoring pattern of eGFR testing.
Although it was possible to use linear regression, we were interested in looking a specific magnitude of change rather than predicting the outcome GFR. Therefore, the first and last eGFR measurements only were to estimate eGFR decline (p 9) and give a gauge of the magnitude of change and since there were only two outcomes (significant or non-significant eGFR decline), logistic regression was used to predict risk. To highlight the limitations of this approach we added to the limitations section (p19): "Finally, use of only the first and last eGFR measurements to calculate eGFR decline may be susceptible to some inaccuracy given the biological and measurement variation possible when measuring serum creatinine. This risk is minimised as the outcome chosen in this study would be clinically relevant and not merely due to baseline variation1,2 " .
3. It would be helpful if the authors justified the statistical methods used more clearly. Why was logistic regression chosen? In this kind of study, while it addresses the research question, it reduces the information presented by restricting it to the binary outcome of progression yes/no. Other methods, such as linear regression, might have been employed in order to better describe the patterns of decline. There may be good reasons for the methods chosen, but they are not clearly justified in the paper.
Authors" response: Thank you for the suggestion on the use of linear regression. As stated in the above response, we were interested in looking a specific magnitude of change rather than predicting the outcome GFR. The outcome of the study was also binary hence logistic regression was deemed an appropriate statistical analysis for the given study objectives. To justify this in the article, the following sentence has been added to the methods -statistics section (p17) "Logistic regression were used as the outcome was binary and this study explored the magnitude of association."
Authors" response: Thank you for this suggestion on the outcome terminology. In light of the limitations of defining CKD from a single baseline eGFR and in those patients with an eGFR of >60, we have changed the term "CKD progression" to "eGFR decline" throughout the manuscript to avoid confusion. However, the overall findings and implications of the paper as stated remain valid. We have made changes to change terms in the paper including the title in line with the reviewers" comments.
5. It is interesting that hypertension is included with other cardiovascular disease. Given the high prevalence of hypertension in people with CKD, it results in a very high apparent prevalence of CVD in this study. In addition, hypertension is both a precipitating factor and a result of renal disease and I would recommend treating it separately in the descriptions and analyses (or at least sensitivity analysis with hypertension treated separately).
Authors" response: It is true that hypertension can be a cause or consequence of CKD. Table 4 which shows the components of CVD shows that the majority of CVD as defined is actually due to hypertension as the reviewer rightly states. Given the number of co-variants already included in the logistic regression model, we decided to include the CVD group as a whole to maintain precision in the adjusted outcomes. However, to help demonstrate to the reader the points made above, the paragraph describing the results on page 15 has been changed to "69.0% (n=2,859) for CVD however the majority (55%) had hypertension".
Authors" response: Thank you for this helpful recommendation that will make the results more relevant to the target audience. In light of this, we have now included examples of what the average daily usage were for normal and high dose NSAID, aspirin or paracetamol use based both on median defined daily doses (DDD) in each group with on mg/gram dose equivalents on page 14 "Average prescribed NSAID doses were 0.18 DDD per day for normal and 1.21 DDD per day for high dose NSAID users equivalent to 0.22g and 1.45 grams of ibuprofen per day respectively. Average prescribed aspirin doses were 0.81 DDD (0.61mg) per day for normal and 1.44 DDD (110mg) per day for high dose aspirin users. Average prescribed paracetamol doses were 0.14 DDD (0.42g) per day for normal and 0.65 DDD (1.95g) per day for high dose paracetamol users".
We have also added a new table (now table 3 -this can be made into a supplementary table if  required) showing the DDD for all the included NSAIDs, aspirin and paracetamol to allow for conversion to mg/gram dose equivalents using DDDs provided within the paper. This has the added benefit of showing the reader all the NSAIDs that were prescribed to the included patients.
7. It is not clear from the descriptive tables how many people had baseline eGFR in each CKD stage. This might be more useful than the current table 2 which just gives information on median eGFR [IQR] Authors" response: Table 2 focuses mainly on the differences between patients who had at least 1 eGFR measurement to those we eventually selected with multiple (2 or more) eGFR measurements. This table was included as it demonstrates the higher burden of co-morbidity in patients with multiple rather than single eGFR measurements. We have added the sentence "Characteristics of patients with single versus multiple eGFR measurements are shown in the Table 2 demonstrating the greater burden of co-morbidity as well as aspirin and paracetamol use in patients with multiple eGFR measurements" (p14).
The median eGFR was included here to simply give an idea of whether there was a difference in the baseline eGFR status in each group. For all included patients, the first eGFR was the baseline eGFR hence all the patients had a baseline eGFR. We have amended the results to read "The median baseline (first) eGFR was 83 [68-91]" (p15).
8. Line 10 page 14 represents a finding that should perhaps be the key finding of the paper -that there was no association between normal or high dose aspirin use and CKD progression in people with CKD 3 -5. Consider refocusing the paper with this being more prominent. For clinicians dealing with CKD in general practice, the implication that we should be considering aspirin treatment in people without current CKD (or very mild impairment of renal function) is perhaps not so relevant. This is treated fairly well in the first paragraph of the discussion, but the overall conclusion and the abstract conclusion then claim that high dose aspirin decreases the risk of CKD progression which is an overstatement given the findings.
Authors" response: Thank you for this suggestion, in light of the overall message that complete avoidance of analgesics may not be necessary in CKD patient we have rewritten the abstract conclusion (p4) to "NSAID, aspirin and paracetamol prescribing over two years did not significantly affect eGFR decline with a reduced risk of eGFR decline in high dose aspirin users with wellpreserved renal function. However, the long-term effects of analgesia use on eGFR decline remain to be determined"
We have e made similar changes to the conclusion section of the study (p23) to give greater emphasis as to the lack of eGFR decline when patients were prescribed NSAIDs, aspirin or paracetamol. Discussion on the interesting effect found in high dose users is still included and mentioned in the conclusion but we have emphasised that this was not a suggestion of association or a claim of an effect but simply that further study is required to elucidate any possible relevance.
9. There is an implication of causality in some of the statements used that is probably inappropriate given the study design. For example -in the first paragraph of the discussion 'high dose aspirin prescribing significantly decreased the risk of CKD progression' might be better worded ' high dose aspirin prescribing was associated with lower risk of eGFR decline' Authors" response: As above, such statements have been reworded.
Minor points
10. Some aspects of the wording could be improved. The first sentence of the background is poorly worded for example.
Authors" response: We have re-written the introductory sentence (p8) to read "Chronic kidney disease (CKD) is a major cause of morbidity and mortality worldwide1 requiring risk factors of CKD progression be identified and minimised.2" Furthermore, we have tried to improve the wording throughout the paper.
11. The sentence about the use of low dose aspirin and NSAIDS in line 37 page 5 (background) makes a statement that cannot be justified from the BNF reference used -is there study evidence that this is true?
Authors" response: The wording in this sentence has been changed to match the use of the BNF reference (p6), the sentence now reads "Low-dose aspirin is indicated for use as a thromboprophylactic agent whilst NSAIDs are indicated for use as simple analgesics6 by patients with a range of musculoskeletal pathology."
12. Was there no ACR data available? Or was it just that there was a lot of missing data? It might be useful to describe the degree of missing ACR data.
Authors" response: This is a useful co-variant that we had considered during the planning stage of the study. Unfortunately we did not have access to reliable albumin creatinine ration (ACR) data at the time hence its lack of inclusion.
13. Consider a sensitivity analysis using the CKDEPI equation to define eGFR given its better risk profile in CKD.
Authors" response: Thank you for this excellent suggestion. At the time we carried out the study, patients who had a serum creatinine measured had an eGFR calculated automatically using the 4 variable MDRD equation. It is this eGFR data that we used in our study not the original serum creatinine hence we are currently unable to carry out such sensitivity analysis. However, in any future work we hope to use the original serum creatinine measurements and the CKDEPI equation to better estimate the GFR.
14. The description of Index of Multiple Deprivation would benefit from saying that it was national IMD if this was the case.
Authors" response: The IMD score was calculated based on data from all neighbourhood in England.
Patients were then divided into the quartiles based on their individual scores relative to each other. We have modified the sentence in the methods, socio-demographics section to clarify this (p10).
15. Page 13 line 12 'the eGFR decline rate profile'. What does this statement mean? Does it refer to table 4? Can the statement be justified?
Authors" response: This sentence refers to the fact that statistical comparisons were based not only on the median eGFR decline rate but the distributions of eGFR decline rates in the non, normal and high dose users. The sentence now reads (p16) "The eGFR decline rate distributions differed significantly between normal, high dose and non-users of aspirin (p=0.028)." 16. Table 3 -age groups would be more helpful than mean (SD). Reword 'CKD progression' Authors" response: We felt that cut-off for age groups would have been arbitrary and people within the same age groups might have different association with eGFR decline hence we decided to keep age as a continuous variable.
The term CKD progression has been reworded to eGFR decline throughout the manuscript.
17. Figure - the flow diagram is helpful, but might benefit from inclusion of the 9 practices with population about 40000 mentioned in the methods. Why were all 9 practices not used -what was the reason for their exclusion? This is not clear in the paper Authors" response: We are sorry for the confusion into how the practices were selected. We only included two practices as these practices had the necessary laboratory data available at the time of the study. We have re-written this whole section in the methods to clarify the above statements which now reads (p6-7):
"Patients were selected anonymised from two general practices which both contribute to the Consultations in Primary Care Archive (CiPCA) and Prescriptions in Primary Care Archive (PiPCA) interlinked databases. The databases contain routinely collected consultation and prescription data recorded since 2000 from 13 general practices in North Staffordshire, UK.11,12 Practices undergo annual assessments, feedback and training on the quality of morbidity recording.13 In addition to consultation (containing diagnostic data) and prescription (containing prescribed analgesia and codrug therapies) data between 2009 and 2010, laboratory data (containing blood tests) for all included patients in the two included general practices (n=23,028 in 2009) chosen were available at the time of the study.11,12"
We also include three new references to qualify the statements made and they give more detailed information on the datasets (including other published work which uses this dataset and how good data entry is maintained in CiPCA). This paper evaluates the effect of NSAIDs, aspirin and paracetamol analgesia dose prescribing on chronic kidney disease (CKD) progression. In general is a well-written and interesting paper. However there are many questions that need to be addressed.
Major comments
Methods: 1. The design used in this analysis is not clearly stated. It seems a case control analysis given that logistic regression and OR are calculated.
Authors" response: We apologise for the confusion in regards to the study design. Our study was a retrospective cohort study, but not a case control study. Unfortunately, our small sample size (i.e. people aged 40 and above with two eGFR measurements and CKD in two general practices) would have resulted in a difficulty in selecting controls individually matched to cases. In addition, we felt that given a case control study would require careful selection of controls with similar co-morbidity burden and co-drug therapy prescription as there is a wide array of drug and pathological factors that can influence CKD and any resultant matching would increase the risk of selection bias.
The abstract (p2) have been changed to be clarify the study design. The title of the article also stated the study design as cohort.
Please see our responses for reviewer 1 comments 2 and 3 for reasons we used logistic regression.
2. Cohort definition: study period is not clearly defined. i.e were patients 40 years and over at January 1st? or could patients be 40 years and over after this date?
Authors" response: The study period was between the 1st of January 2009 until the 31st of December 2010. Patients had to be at least 40y by the 1st of January, those aged under 40 on this date were excluded from the dataset. To make this clearer in the methods we have rewritten the selection section (p8) to read "Patients aged 40 years and over with at least one eGFR measurement from the January 1st 2009 up to December 31st 2010 were identified (2-year study period). Of these, patients with two or more eGFR measurements during the 2-year study period were eligible for inclusion and formed the study cohort (Figure 1 ). Patients aged under 40 years old on January 1st 2009 were excluded because stage 3-5 CKD prevalence is low in this age group.14" 3. Are patients newly diagnosed CKD patients?
Authors" response: This was a prevalent study design. We did not look at whether there had been a prior diagnosis of CKD or not, we used the patients" first eGFR measurements to categorise patients into CKD groups. Hence it may be the case that some patients had new and some had pre-existing CKD. We have listed this point within the limitation section (p19 line 9).
4. Cumulative exposure definition: a. With respect to cumulative exposure definition. It is described that "All prescriptions from January 1st up to the last eGFR" were included in the cumulative exposure (page 8 line 25). However it is also stated that prescription given before the study "start date" and the date of the fist eGFR were included (page 9, line 18). Please define "start date", and "last eGRF" (does it mean second, third??) and clarify this point. This is really important to set the aim of this research in whether analgesia use is associated with CKD progression or whether analgesia use increases the risk of developing CKD. b. As far as I understood, cumulative duration (and dose) of analgesia, as it was measured in this study, means to consider all prescription regardless of whether or not they were consecutively prescribed. However this is not exactly similar to continuous duration in which a number of days (gap) between the end of a prescription and the start of the consecutive one has to be permitted to define "continuous" use. Aspirin prescriptions are probably used for prophylaxis so we can assume "continuous", however NSAIDs can be discontinuous. Moreover, this is important as the term "shortterm" is used in the title and this usually refers to "continuous duration". The term "long-term users" in also used in the discussion section referring to other studies". Please define these terms (short/long term) in the methods section or use other names according to those defined in methods.
Authors" response: Again we apologise that the design of exposure measurements did not come across. The problem we faced in measuring exposure was that patients may be given a prescription between the 1st of January 2009 and the December 31st 2010. However, the last eGFR (the last eGFR meaning that last measurement before December 31st 2010 per patient) measurement may done before the 31st of December 2010. Therefore, any analgesics taken after the last eGFR date should not be counted as their supposed effect on the eGFR would not have affected the last eGFR measurement. Therefore we only include the prescriptions issued between the 1st of January and the date of the last eGFR per individual; this was in essence the exposure period.
The second problem is that prescriptions may be given from the 1st of January but this may predate the date of the FIRST eGFR. However, we include these prescriptions because theoretically, the analgesia use may set up a RATE of eGFR change which would be detected once the first and last eGFR measurements were compared.
We have modified the methods -exposure definition section (p11 paragraph 2) to show when the study start and defined the exposure period clearly.
Finally, it is correct that prescriptions for analgesics may be continuous or may have large interludes between prescriptions. In this study we did not define "continuous" use but used all prescriptions given in the pre-defined periods. There is some variety in the terminology used to represent analgesia use be it long term or short term. The use of short term use in this study simply refers to the 2 year period of this study. Other studies have had 5-7 year study periods hence we refer to them as longer term (simply in comparison to this study) in all other regards we try and focus on dose comparisons. One of the recommendations is that long term (in terms of study length) study is required as even with two years of possible time for prescriptions to be given, patients actually did not have continuous use throughout this time. To help give a gauge of the levels of use, we now include a conversion in terms of real world analgesia use per day (e.g. 0.22 grams/day of ibuprofen for normal dose users) to help give a comparison of what level of what level of continuous use would be required to give the equivalent observed effects in this study (Please see reviewer 1, reply 6).
5. Regarding to covariates, a. Description of codes used for potential confounders are welcome. This helps to reproduce variables in similar studies (supplementary table online??). b. On page 10, line 17, it is described that co-morbidity will be defined as the presence of those diseases "at any point throughout the study period", similarly to co-drugs ("during the study period", line 38 of the same page). Will patient"s follow-up be censored at the last eGFR measure? Or, I assume they will be measured before the last eGRF. Could you please clarify this point?. In addition, co-morbidities are chronic, however co-medication could be measured far from the endpoint. Could you please clarify this point as well?
Authors" response: Thank you for this most useful suggestion. To help the reader and other future studies reproduce similar variables, we have included in the co-morbidity methods (p12) section a specification of the major codes used to define comorbidity using the READ code system for better clarity. We also provide a new figure (Figure 2 -this may be made into an online supplementary figure if required) to demonstrate how co-morbidity was defined.
In terms of co-morbidity, any code for comorbidity between Jan 1st 2009 and Dec 31st 2010 counted as presence of comorbidity (This is the study period -defined in the methods) hence follow-up in this sense was throughout the study period. Presence of co-drug therapy was defined as one or more prescriptions of renin angiotensin system inhibitors (RAS-i) between the 1st Jan 2009 to 31st Dec 2010. Due to the nature of the chronic diseases in which RAS-I are used, they were in effect treated in a similar fashion to the presence of co-morbidity. Therefore, here was no censoring of follow-up as presence of co-morbidity or co-drug prescription was counted were it to occur at any point in the study period.
6. Define in methods which is the "baseline CKD stage" (page 11, line23)
Authors" response: The first eGFR was used as the baseline eGFR, this has now been clarified in the methods (p9).
Discussion 7. High dose NSAIDs has been related to CKD progression however this was not observed in this analysis, could it be due to different cut-off point for dose used in previous studies?
Authors" response: It is correct that high dose NSAID use has been associated with CKD progression (See the systematic review by Nderitu et al 2013) but this was not observed in this study. The chosen cut-offs in our study are in fact based on and match those by Gooch et al (wjich contributed to the systematic review by Nderitu et al) in which high dose NSAID use lead to eGFR decline. However, in our study, the mean age of participants was lower (66 vs 76 years) and the sample size of high dose NSAID users with stage 3-5 CKD was limited both of which may have affected the ability to detect an effect. It is also not possible to comment of the PATTERNS of NSAID use between the two studies (e.g. whether there was more or less continuous or non-continuous use) which may play a part in the way NSAIDs affect CKD progression (See reviewer 2 comment 4b). This final point on patterns of use has been added to the discussion section on NSAIDS and eGFR decline (p20) and may help explain some of the differences in findings.
8. A more detailed description on possible differences in methods applied in previous studies, which could explain different results, is desirable (i.e different definition for cumulative/continuous duration, cut-off points and different designs).
Authors" response: Thank you for this useful addition. We have elaborated in discussion section for each analgesic group (p20, 21 and 22) on how study analgesia dose definitions and patterns of use may have resulted in difference.
Minor comments Methods 9. A more detailed explanation on total patients included in the database as well as number of GPs, etc will be welcome.
Authors" response: A similar query to the first reviewer (comment 17). Briefly, as of 2012 there were 13 practices that contributed to CiPCA. The two chosen practices had the necessary laboratory data available at the time of the study. They had a population of 23,028 registered patients of which, after application of the selection criteria, 4145 patients made up the study cohort (Figure 1 ). This detail is now included in the methods study design section (p22) with 3 new references included to give more detail on the CiPCA database.
Results:
10. Total numbers (counts) should be added to tables in addition to OR. Table 5 needs numbers for CKD progression and CKD non-progression.
Authors" response: Within table 6, we include the total numbers in each group are included per drug category on the left had side e.g. Non-users of NSAIDs with normal/mild eGFR = 2821. We have added numbers to the CKD progression/non-progression (now called significant and non-significant eGFR decline - Table 4 ) on co-morbidity and co-drug therapy to aid with the interpretation.
11. "reserve" has to be changed by "preserve" (page 15, line 27) Authors" response: We apologise for this error, this has now been corrected.
12. Another limitation (although it is probably a minor limitation) is analgesia prescribed in hospital, what is probably missing in a primary care based database.
Authors" response: It is true that only issued prescriptions were included but hospital admission for AKI would have been excluded and NSAIDs tend not to be given in hospital. In large, given the two year study period, prescriptions would have mainly been issued by the GP and because most prescriptions are monthly, the hospital stay would have needed to be significant for this to affect the cumulative dose calculation. We agree however that this may be a minor limitation of our study. Discussion: 13. Once patients are diagnosed with chronic renal insufficiency, they are probably advised to discontinue (or not to use) NSAIDs as these drugs interfere with potassium excretion and may further compromise glomerular filtration rate. In guidelines but also in patients information leaflet for NSAIDs it is recommended to use these drugs with caution if CKD exists. Might this situation have an impact on results?
Authors" response: This is good observation and is a limitation of any such study. It is also the likely cause for the low numbers of patients with high dose NSAIDs with poor renal function that we were able to recruit (n=11) and may limit the ability to detect negative effects in these patients.
However, in more modest dosages, we saw a greater number of prescriptions, even in patients with stage 3 CKD. It is these groups of patients in which we wanted to study and demonstrate that with a low but effective dose of NSAIDs, complete avoidance may not be necessary as there is not a decline in eGFR but patients can still benefit from the significant analgesic effects, especially in patients with inflammatory musculoskeletal pathologies. Therefore, it is true that avoidance of NSAID prescriptions by GP may affect the results but this is more likely to be in the high dose user group with poor renal function. In patients with moderate analgesia use we still see analgesia prescribing and yet no great degree of eGFR decline.
14. With respect to the significant lack of progression using higher dose of aspirin in normal or mildly impaired eGFR in contrast with the non-significant effect in stage 3-5 CKD, as the authors stated, "it is unclear as to whether aspirin is renoprotective independent of its cardioprotective effect". Thus potential differences between patients with/without CVD could be explored, which provides different information than just simple inclusion of those variables in the models.
Authors" response: This was an interesting effect which was shown in our study findings, we agree that further exploration into this effect is required but this is currently beyond the scope of this current paper but this forms one of our recommendations for future work in this area.
15. As the authors stated, non significant effect of high dose use of aspirin in patients at stage 3-5 CDK could be indeed due to few numbers; however, might this group be less prone to be influence by the cardioprotective effect of aspirin as they have CKD already established?
Authors" response: An excellent suggestion as to the lack of possible effect. We agree that it may be the case that patients with established stage 3-5 CKD are less prone to influence by the use of "high dose" aspirin and hence the reason we do not see a decreased risk of eGFR decline in this group although this could also be compounded by the relatively shorter follow-up period. Therefore, the effect may only be detected at higher doses of use or with a longer follow-up time thus our recommendations for longer term studies to look into this potentially useful renoprotective effect.
We hope we have addressed all concerns and look forward to hearing from you. 
GENERAL COMMENTS
Thank you for the opportunity to provide a further review of this paper. It is an interesting study and represents a useful addition to the literature.
The authors have responded well to the issues I raised. The paper is now clearer to read and the methods, conclusions and limitations are considerably improved.
I have only a few minor comments to make on specific sentences:
In the strengths and limitations: page 5 and also line 35 pg 17, the statement that people had a 'wide spectrum of CKD' should perhaps be 'wide spectrum of CKD and non CKD' given that some people had normal baseline eGFR and uncertain ACR status.
Check for consistency of use of past and present tense e.g. line 14 pg 5 and line 13 vs 7 'aims vs aimed'
The methods have been greatly improved but one phrase (Line 31 pg 7) 'selected anonymised' could perhaps be clearer.
Could the authors check that the average aspirin dose is correct pg 14 line 5 '0.81DDD (0.61mg)' 0.61mg seems very small -should it be 61mg or 0.61g?
Wording of line 38 page 14 'prevalence of eGFR decline' -should it be 'incidence' as these are new cases of eGFR decline?
The final sentence of the discussion line 43 pg 21 'no sig association between paracetamol use and CKD' should it read '...between paracetamol use and CKD progression'
Conclusion -add 'renal function' to the words 'well preserved' line 3 page 22 Table 1 and table 3 could possibly be supplementary tables, but I do not have strong feelings about this and I will leave it to the editor to advise on this according to BMJ open house style.
I do not feel the need to further review the paper if these minor issues are addressed and I would recommend publication. 
REVIEWER
